An Update on Antimicrobial Peptides (AMPs) and Their Delivery Strategies for Wound Infections.
Viorica PatruleaGerrit BorchardOlivier JordanPublished in: Pharmaceutics (2020)
Bacterial infections occur when wound healing fails to reach the final stage of healing, which is usually hindered by the presence of different pathogens. Different topical antimicrobial agents are used to inhibit bacterial growth due to antibiotic failure in reaching the infected site, which is accompanied very often by increased drug resistance and other side effects. In this review, we focus on antimicrobial peptides (AMPs), especially those with a high potential of efficacy against multidrug-resistant and biofilm-forming bacteria and fungi present in wound infections. Currently, different AMPs undergo preclinical and clinical phase to combat infection-related diseases. AMP dendrimers (AMPDs) have been mentioned as potent microbial agents. Various AMP delivery strategies that are used to combat infection and modulate the healing rate-such as polymers, scaffolds, films and wound dressings, and organic and inorganic nanoparticles-have been discussed as well. New technologies such as Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated protein (CRISPR-Cas) are taken into consideration as potential future tools for AMP delivery in skin therapy.
Keyphrases
- wound healing
- crispr cas
- protein kinase
- genome editing
- multidrug resistant
- staphylococcus aureus
- gram negative
- pseudomonas aeruginosa
- microbial community
- genome wide
- surgical site infection
- human health
- gene expression
- candida albicans
- cell therapy
- climate change
- current status
- escherichia coli
- stem cells
- biofilm formation
- room temperature
- tissue engineering
- bone marrow
- mesenchymal stem cells
- dna methylation
- cystic fibrosis
- klebsiella pneumoniae
- ionic liquid
- replacement therapy